Welcome to our dedicated page for Translational Development Acquisition SEC filings (Ticker: TDAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Translational Development Acquisition's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Translational Development Acquisition's regulatory disclosures and financial reporting.
Translational Development Acquisition Corp. (TDAC) distributed information from ProLogium Holding Inc. describing a strategic investment by Kyushu Electric Power in ProLogium, extending their relationship from industrial collaboration into capital participation. The companies plan to continue joint work on next-generation batteries, including exploring battery module manufacturing in Japan for demanding industrial and construction machinery applications.
The communication also outlines ProLogium’s next-generation lithium ceramic battery business, its Taoyuan GWh-class gigafactory and a second gigafactory in Dunkirk, France, and reminds TDAC shareholders that a registration statement on Form F-4 with a proxy statement/prospectus has been filed for the proposed business combination between ProLogium and TDAC.
Translational Development Acquisition Corp. is a SPAC that has not yet begun operating activities and is focused on completing its first business combination. As of June 30, 2026, assets totaled $157.4 million, largely in a trust account invested in money market funds, with cash outside the trust of $85,877 and a working capital deficit.
For the six months ended June 30, 2026, the company reported net income of $2.3 million, driven by $3.3 million of dividends on trust investments, partially offset by $0.9 million of general and administrative costs. During June 2026, holders redeemed 2,598,697 Class A shares for $27.8 million, reducing trust assets.
The SPAC entered into a Business Combination Agreement with ProLogium Holding Inc. and a related $50 million subscription for 5,000,000 Class A shares plus an equal number of warrants, both contingent on closing the transaction. The combination deadline was extended to June 24, 2027, but management discloses substantial doubt about the ability to continue as a going concern if no deal is completed by that date.
Meteora Capital, LLC and its managing member Vik Mittal report beneficial ownership of 919,000 shares of Translational Development Acquisition Corp. Class A Common Stock, representing 6.27 % of the class. All reported shares are held by funds and managed accounts for which Meteora Capital acts as investment manager, with no sole voting or dispositive power and shared voting and dispositive power over all 919,000 shares. The reporting persons state that the filing does not constitute an admission that they are beneficial owners of these shares for purposes of Section 13.
Linden Capital L.P., Linden GP LLC, Linden Advisors LP and Siu Min (Joe) Wong report beneficial ownership of 1,150,000 Class A Ordinary Shares of Translational Development Acquisition Corp. as of June 30, 2026. This represents approximately 6.7% of the outstanding Class A shares for each of Linden Advisors and Mr. Wong, and 1,109,668 shares, or 6.4%, for each of Linden Capital and Linden GP. The 1,150,000 shares consist of 1,109,668 shares held by Linden Capital and 40,332 shares held in separately managed accounts. All reported voting and dispositive powers are shared, with no sole voting or dispositive power reported by any party.
The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC report beneficial ownership of 1,056,879 Class A ordinary shares of Translational Development Acquisition Corp. Both entities report 7.2% of the class.
They report 0 shares with sole voting or dispositive power and 1,056,879 shares with shared voting and shared dispositive power. Goldman Sachs & Co. LLC is identified as a broker-dealer and registered investment adviser, and as a subsidiary through which the parent holding company’s reportable ownership is held.
The reporting units of Goldman Sachs state that they disclaim beneficial ownership of securities held for certain client accounts or investment entities where interests are held by other persons.
ProLogium Holding Inc. and Translational Development Acquisition Corp. (TDAC) outline a US$50 million committed primary capital investment from a consortium of existing shareholders to support their proposed business combination and ProLogium’s commercialization plans for next-generation lithium ceramic batteries.
ProLogium highlights its technology position, with over 1,100 global patents, more than 2.4 million battery products delivered and about 10,000 samples supplied for automotive applications. Its Taoke facility in Taiwan is described as the first commercial next-generation lithium ceramic battery gigafactory to publicly display its production line.
The company is expanding in Europe through an R&D center in Paris-Saclay and a gigafactory project in Dunkirk, France, where Phase 1 is designed for 4.0 GWh capacity by 2030 and the full site for up to 44.0 GWh. The communication also notes that ProLogium has filed a Form F-4 registration statement that includes a proxy statement/prospectus for TDAC shareholders regarding the transaction.
ProLogium Holding Inc. and special purpose acquisition company Translational Development Acquisition Corp. (TDAC) announced a $50 million committed primary capital investment from a consortium of existing ProLogium shareholders to support their proposed business combination that would result in ProLogium becoming publicly listed. The capital is part of a broader raise tied to the transaction and is expected to help scale production of ProLogium’s next-generation lithium ceramic batteries, advance construction of its gigafactory in Dunkirk, France, and fund expansion into applications such as data centers, aerospace and robotics.
ProLogium highlights more than 1,100 global patents, over 2.4 million battery products delivered and a first GWh‑class gigafactory in Taoyuan, Taiwan. The Dunkirk site is planned for a Phase 1 capacity of 4.0 GWh by 2030 and a maximum designed capacity of 44.0 GWh. The communication also references ProLogium’s filed Form F‑4 registration statement and associated proxy statement/prospectus for TDAC shareholders.
Translational Development Acquisition Corp. (TDAC) entered into a Subscription Agreement with ProLogium Holding Inc. and Naetas Holding Limited in connection with their proposed business combination. Naetas agreed to purchase 5,000,000 TDAC Class A ordinary shares at $10.00 per share for an aggregate $50,000,000 private placement.
For no additional consideration, Naetas is also expected to receive 5,000,000 warrants with terms substantially identical to TDAC’s public warrants, including a $11.50 exercise price, a $18.00 redemption trigger and a $0.01 redemption price per warrant. Closing of the subscription is expected one business day before the first merger in the business combination and is subject to customary conditions and consummation of the merger.
The purchase price will be funded into escrow and returned, with any issued Subscribed Securities cancelled, if the business combination is not completed within the specified period. ProLogium agreed to use commercially reasonable efforts to register the resale of the ProLogium shares and warrants issued in exchange for the Subscribed Securities within 45 days after the business combination closing, subject to SEC review timelines.
Translational Development Acquisition Corp. entered into a Subscription Agreement with ProLogium Holding Inc. and Naetas Holding Limited, under which Naetas agreed to purchase 5,000,000 TDAC Class A ordinary shares at $10.00 per share, for an aggregate $50,000,000 private placement tied to TDAC’s pending business combination with ProLogium.
For no additional consideration, Naetas is also entitled to receive 5,000,000 Subscribed Warrants with terms substantially identical to TDAC’s public warrants, including a $11.50 exercise price, an $18.00 per-share redemption trigger and a $0.01 per-warrant redemption price, without ratchets or price resets beyond customary anti-dilution. The subscription is expected to close one business day before the first merger and is fully contingent on completion of the ProLogium business combination; funds will be held in escrow and returned, and any Subscribed Securities cancelled, if the deal does not close in the specified period.
The securities will be sold in an unregistered private placement relying on Section 4(a)(2) of the Securities Act to an institutional accredited investor. ProLogium agreed to use commercially reasonable efforts to register the resale of the resulting ProLogium shares and warrants, generally filing within 45 days after the business combination closing and targeting SEC effectiveness within defined timeframes.
Wolverine Asset Management, LLC, Wolverine Holdings, LLC, and managers Christopher L. Gust and Robert R. Bellick report beneficial ownership of 944,878 Translational Development Acquisition Corp. Class A Ordinary Shares. Each reporting person has shared voting and dispositive power over these shares, with no sole voting or dispositive authority.
The disclosure states this represents 4.89% of the outstanding Class A Ordinary Shares. The percentage is based on 19,308,802 shares outstanding, derived from 21,907,499 shares outstanding as of June 12, 2026, minus 2,598,697 shares redeemed at the June 17, 2026 shareholders' meeting. The reporting persons indicate they own 5 percent or less of this class.